TOKYO -- Investment funds Curi RMB Capital and Oasis Management are contesting the pricing of Taisho Pharmaceutical Holdings' management buyout in court, Nikkei has learned, after failed negotiations over their forced divestment as minority shareholders.
Taisho Pharma announced plans for the management buyout in November 2023, with a company led by founding family member Shigeru Uehara completing the tender offer this January. The tender offer price of 8,620 yen per share reflected a 50%-plus premium for the stock but still priced the company below book value.
